2.1
Ublituximab (Briumvi, Neuraxpharm) is indicated for 'the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features'.
2 Information about ublituximab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for ublituximab.
Price
2.3
The list price of ublituximab is £2,947.00 per 150-mg vial (excluding VAT, company submission, accessed November 2024).
2.4
The company has a commercial arrangement. This makes ublituximab available to the NHS with a discount. The size of the discount is commercial in confidence.